San Francisco startup Composition Therapeutics is also working on an oral, at the time-every day GLP-one drug known as GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June when a mid-phase examine showed average weight loss of all over 6% and it programs to begin A different mid-stage trial toward the tip of this year—that founder